A Phase 3 interventional study of Nivolumab and Radical cystectomy (RC) in Bladder Cancer, Bladder Tumor and Muscle-Invasive Bladder Cancer, sponsored by Bristol-Myers Squibb. Completed at 116 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 19th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 4
First in 2015; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 76 across the 25 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, 1 of them phase 3. Of 10 finished, 3 (30%) have results posted.
Among the 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2020, is one of 3 in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Urinary Bladder Neoplasms studies by the year they started, since 2005.
4 of the studies testing nivolumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06237920The Netherlands Cancer InstituteStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | 2026-12-01 |
| NCT03520491Memorial Sloan Kettering Cancer CenterA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | 2027-01 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT02496208National Cancer Institute (NCI)Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 11 in Urinary Bladder Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, including muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cisplatin-ineligible participants will be defined by any one of the following criteria:
i) Impaired renal function ( [GFR] ≥ 30 but \< 60 mL/min) ii) GFR should be assessed by direct measurement (ie, ) or, if not available, by calculation from serum/plasma creatinine (Cockcroft-Gault formula) iii) (CTCAE) version 5, ≥ Grade 2 hearing loss (assessed per local SOC).
iv) CTCAE version 5, ≥ Grade 2 peripheral neuropathy.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg
Biological: Nivolumab · Procedure: Radical cystectomy (RC) · Biological: Bempegaldesleukin
Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab
Biological: Nivolumab · Procedure: Radical cystectomy (RC)
RC alone, without neoadjuvant or adjuvant therapy
Procedure: Radical cystectomy (RC)
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Surgical removal of the bladder
Specified dose on specified days
Also known as: BMS-986321, NKTR-214, Bempeg
Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care
Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.
Time frame: From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)
Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care
Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).
Time frame: From randomization up to first EFS event (up to approximately 30 months)
Pathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care
Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.
Time frame: From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)
Event Free Survival (EFS) - Nivolumab Compared to Standard of Care
Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).
Time frame: From randomization up to first EFS event (up to approximately 30 months)
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive. OS was not calculated for Arm A and Arm B because the number of events did not meet the threshold due to early study termination. In lieu of OS, time to death is reported as a Post-Hoc endpoint.
Time frame: From randomization to study completion, up to approximately 40 months
The Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: from first dose to 100 days following last dose (up to approximately 20 months)
The Number of Participants Experiencing Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: from first dose to 100 days following last dose (up to approximately 20 months)
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: from first dose to 100 days following last dose (up to approximately 20 months)
The Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs)
IMAEs are specific AEs that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine (adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-mediated events by investigator that meet the definition summarized below: * those occurring within 100 days of the last dose, * regardless of causality, * treated with immune-modulating medication (of note, endocrine AEs such as adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating medication use, since endocrine drug reactions are often managed without immune-modulating medication). * with no clear alternate etiology based on investigator assessment, or with an immune-mediated component.
Time frame: from first dose to 100 days following last dose (up to approximately 20 months)
Worst Grade Clinical Laboratory Values
Clinical laboratory values by worst CTC grade are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose to 100 days following last dose (up to approximately 20 months)
| Milestone | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| Started | 37 | 37 | 40 |
| Completed | 37 | 37 | 32 |
| Not completed | 0 | 0 | 8 |
| Withdrew: Completed without radical cystectomy | 0 | 0 | 5 |
| Withdrew: Other reasons | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 |
| Milestone | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| Started | 37 | 37 | 32 |
| Completed | 15 | 13 | 32 |
| Not completed | 22 | 24 | 0 |
| Withdrew: Other reasons | 5 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 1 | 5 | 0 |
| Withdrew: Death | 4 | 1 | 0 |
| Withdrew: Study drug toxicity | 4 | 6 | 0 |
| Withdrew: Disease progression | 6 | 9 | 0 |
Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.
| Percentage of participants | Arm A: Nivolumab + Bempegaldesleukin | Arm C: Standard of Care |
|---|---|---|
| Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care | 10.8 (3.0 to 25.4) | 2.5 (0.1 to 13.2) |
Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).
| Months | Arm A: Nivolumab + Bempegaldesleukin | Arm C: Standard of Care |
|---|---|---|
| Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care | 22.11 (8.21 to NA) | 15.18 (11.63 to NA) |
Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.
| Percentage of participants | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|
| Pathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care | 10.8 (3.0 to 25.4) | 2.5 (0.1 to 13.2) |
Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).
| Months | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|
| Event Free Survival (EFS) - Nivolumab Compared to Standard of Care | NA (10.84 to NA) | 15.18 (11.63 to NA) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive. OS was not calculated for Arm A and Arm B because the number of events did not meet the threshold due to early study termination. In lieu of OS, time to death is reported as a Post-Hoc endpoint.
| Months | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | 23.23 (14.36 to NA) |
The amount of time in months from when participants were randomized until death. Survival was reported as time to death instead of overall survival by Kaplan-Meier analysis due to the small number of events at the time of early study completion.
| Months | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| Time to Death | 6.77 (3.2 to 18.4) | 9.43 (1.8 to 20.1) | 8.49 (1.6 to 23.2) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) | 34 | 36 | 19 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | 15 | 18 | 14 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 8 | 8 | 0 |
IMAEs are specific AEs that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine (adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-mediated events by investigator that meet the definition summarized below: * those occurring within 100 days of the last dose, * regardless of causality, * treated with immune-modulating medication (of note, endocrine AEs such as adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating medication use, since endocrine drug reactions are often managed without immune-modulating medication). * with no clear alternate etiology based on investigator assessment, or with an immune-mediated component.
| Participants | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| The Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs) | 10 | 10 | 0 |
Clinical laboratory values by worst CTC grade are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| Hemoglobin — Grade 0 | 5 | 5 | 0 |
| Hemoglobin — Grade 1 | 23 | 23 | 2 |
| Hemoglobin — Grade 2 | 7 | 8 | 3 |
| Hemoglobin — Grade 3 | 1 | 1 | 1 |
| Hemoglobin — Grade 4 | 0 | 0 | 0 |
| Hemoglobin — Not Reported | 1 | 0 | 26 |
| Platelet Count — Grade 0 | 35 | 34 | 5 |
| Platelet Count — Grade 1 | 1 | 3 | 1 |
| Platelet Count — Grade 2 | 0 | 0 | 0 |
| Platelet Count — Grade 3 | 0 | 0 | 0 |
| Platelet Count — Grade 4 | 0 | 0 | 0 |
| Platelet Count — Not Reported | 1 | 0 | 26 |
| Leukocytes, Local Lab — Grade 0 | 33 | 35 | 6 |
| Leukocytes, Local Lab — Grade 1 | 2 | 2 | 0 |
| Leukocytes, Local Lab — Grade 2 | 0 | 0 | 0 |
| Leukocytes, Local Lab — Grade 3 | 1 | 0 | 0 |
| Leukocytes, Local Lab — Grade 4 | 0 | 0 | 0 |
| Leukocytes, Local Lab — Not Reported | 1 | 0 | 26 |
| Lymphocytes (Absolute), Local Lab — Grade 0 | 23 | 12 | 0 |
| Lymphocytes (Absolute), Local Lab — Grade 1 | 4 | 6 | 0 |
| Lymphocytes (Absolute), Local Lab — Grade 2 | 0 | 6 | 0 |
| Lymphocytes (Absolute), Local Lab — Grade 3 | 3 | 2 | 0 |
| Lymphocytes (Absolute), Local Lab — Grade 4 | 0 | 0 | 0 |
| Lymphocytes (Absolute), Local Lab — Not Reported | 7 | 11 | 32 |
| Absolute Neutrophil Count — Grade 0 | 31 | 36 | 0 |
| Absolute Neutrophil Count — Grade 1 | 4 | 1 | 0 |
| Absolute Neutrophil Count — Grade 2 | 0 | 0 | 0 |
| Absolute Neutrophil Count — Grade 3 | 0 | 0 | 0 |
| Absolute Neutrophil Count — Grade 4 | 1 | 0 | 0 |
| Absolute Neutrophil Count — Not Reported | 1 | 0 | 32 |
| Alkaline Phosphate, Local Lab — Grade 0 | 24 | 30 | 2 |
| Alkaline Phosphate, Local Lab — Grade 1 | 10 | 7 | 0 |
| Alkaline Phosphate, Local Lab — Grade 2 | 2 | 0 | 0 |
| Alkaline Phosphate, Local Lab — Grade 3 | 0 | 0 | 0 |
| Alkaline Phosphate, Local Lab — Grade 4 | 0 | 0 | 0 |
| Alkaline Phosphate, Local Lab — Not Reported | 1 | 0 | 30 |
| Aspartate Aminotransferase, Local Lab — Grade 0 | 31 | 30 | 2 |
| Aspartate Aminotransferase, Local Lab — Grade 1 | 5 | 6 | 0 |
| Aspartate Aminotransferase, Local Lab — Grade 2 | 0 | 1 | 0 |
| Aspartate Aminotransferase, Local Lab — Grade 3 | 0 | 0 | 0 |
| Aspartate Aminotransferase, Local Lab — Grade 4 | 0 | 0 | 0 |
| Aspartate Aminotransferase, Local Lab — Not Reported | 1 | 0 | 30 |
| Alanine Aminotransferase, Local Lab — Grade 0 | 26 | 30 | 2 |
| Alanine Aminotransferase, Local Lab — Grade 1 | 10 | 7 | 0 |
| Alanine Aminotransferase, Local Lab — Grade 2 | 0 | 0 | 0 |
| Alanine Aminotransferase, Local Lab — Grade 3 | 0 | 0 | 0 |
| Alanine Aminotransferase, Local Lab — Grade 4 | 0 | 0 | 0 |
| Alanine Aminotransferase, Local Lab — Not Reported | 1 | 0 | 30 |
| Total Bilirubin, Local Lab — Grade 0 | 33 | 35 | 2 |
| Total Bilirubin, Local Lab — Grade 1 | 2 | 2 | 0 |
| Total Bilirubin, Local Lab — Grade 2 | 1 | 0 | 0 |
| Total Bilirubin, Local Lab — Grade 3 | 0 | 0 | 0 |
| Total Bilirubin, Local Lab — Grade 4 | 0 | 0 | 0 |
| Total Bilirubin, Local Lab — Not Reported | 1 | 0 | 30 |
| Creatinine, Local Lab — Grade 0 | 11 | 13 | 5 |
| Creatinine, Local Lab — Grade 1 | 10 | 14 | 1 |
| Creatinine, Local Lab — Grade 2 | 12 | 9 | 0 |
| Creatinine, Local Lab — Grade 3 | 3 | 1 | 0 |
| Creatinine, Local Lab — Grade 4 | 0 | 0 | 0 |
| Creatinine, Local Lab — Not Reported | 1 | 0 | 26 |
| Hypernatremia — Grade 0 | 34 | 36 | 6 |
| Hypernatremia — Grade 1 | 2 | 1 | 0 |
| Hypernatremia — Grade 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 | 0 | 0 | 0 |
| Hypernatremia — Not Reported | 1 | 0 | 26 |
| Hyponatremia — Grade 0 | 24 | 29 | 5 |
| Hyponatremia — Grade 1 | 12 | 7 | 1 |
| Hyponatremia — Grade 2 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 | 0 | 1 | 0 |
| Hyponatremia — Grade 4 | 0 | 0 | 0 |
| Hyponatremia — Not Reported | 1 | 0 | 26 |
| Hyperkalemia — Grade 0 | 24 | 25 | 6 |
| Hyperkalemia — Grade 1 | 7 | 9 | 0 |
| Hyperkalemia — Grade 2 | 4 | 3 | 0 |
| Hyperkalemia — Grade 3 | 1 | 0 | 0 |
| Hyperkalemia — Grade 4 | 0 | 0 | 0 |
| Hyperkalemia — Not Reported | 1 | 0 | 26 |
| Hypokalemia — Grade 0 | 24 | 25 | 6 |
| Hypokalemia — Grade 1 | 7 | 9 | 0 |
| Hypokalemia — Grade 2 | 4 | 3 | 0 |
| Hypokalemia — Grade 3 | 1 | 0 | 0 |
| Hypokalemia — Grade 4 | 0 | 0 | 0 |
| Hypokalemia — Not Reported | 1 | 0 | 26 |
| Hypercalcemia — Grade 0 | 33 | 34 | 4 |
| Hypercalcemia — Grade 1 | 3 | 3 | 0 |
| Hypercalcemia — Grade 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 | 0 | 0 | 0 |
| Hypercalcemia — Not Reported | 1 | 0 | 28 |
| Hypocalcemia — Grade 0 | 29 | 28 | 0 |
| Hypocalcemia — Grade 1 | 6 | 7 | 3 |
| Hypocalcemia — Grade 2 | 1 | 1 | 1 |
| Hypocalcemia — Grade 3 | 0 | 1 | 0 |
| Hypocalcemia — Grade 4 | 0 | 0 | 0 |
| Hypocalcemia — Not Reported | 1 | 0 | 28 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 40 months). Serious adverse events (SAEs) and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 20 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivolumab + Bempegaldesleukin | 8/37 (21.6%) | 16/37 (43.2%) | 32/37 (86.5%) |
| Arm B: Nivolumab | 6/37 (16.2%) | 22/37 (59.5%) | 29/37 (78.4%) |
| Arm C: Standard of Care | 12/40 (30%) | 15/32 (46.9%) | 18/32 (56.3%) |
| Event | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| SepsisInfections and infestations | 2/37 | 1/37 | 4/32 |
| Urinary tract infectionInfections and infestations | 4/37 | 1/37 | 3/32 |
| Acute myocardial infarctionCardiac disorders | 0/37 | 3/37 | 0/32 |
| Intestinal obstructionGastrointestinal disorders | 0/37 | 3/37 | 0/32 |
| PyelonephritisInfections and infestations | 0/37 | 3/37 | 0/32 |
| Acute kidney injuryRenal and urinary disorders | 2/37 | 3/37 | 0/32 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 0/37 | 2/32 |
| Atrial fibrillationCardiac disorders | 2/37 | 0/37 | 0/32 |
| Cardiac arrestCardiac disorders | 0/37 | 1/37 | 1/32 |
| ConstipationGastrointestinal disorders | 0/37 | 0/37 | 1/32 |
| Event | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 13/37 | 6/37 | 0/32 |
| PyrexiaGeneral disorders | 10/37 | 3/37 | 4/32 |
| AstheniaGeneral disorders | 9/37 | 5/37 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 8/37 | 3/37 | 0/32 |
| FatigueGeneral disorders | 8/37 | 6/37 | 3/32 |
| AnaemiaBlood and lymphatic system disorders | 4/37 | 7/37 | 2/32 |
| ConstipationGastrointestinal disorders | 4/37 | 7/37 | 4/32 |
| Urinary tract infectionInfections and infestations | 5/37 | 7/37 | 2/32 |
| Weight decreasedInvestigations | 4/37 | 7/37 | 2/32 |
| HypertensionVascular disorders | 1/37 | 6/37 | 0/32 |
| Age, Continuous(Years) | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care | Total |
|---|---|---|---|---|
| Median | 73.0 ± 8.8 | 72.0 ± 7.5 | 74.5 ± 8.4 | 74.0 ± 8.2 |
| Sex: Female, Male(Participants) | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care | Total |
|---|---|---|---|---|
| Female | 6 | 7 | 9 | 22 |
| Male | 31 | 30 | 31 | 92 |
| Race (NIH/OMB)(Participants) | Arm A: Nivolumab + Bempegaldesleukin | Arm B: Nivolumab | Arm C: Standard of Care | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 36 | 35 | 36 | 107 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 | 6 |
Showing the first 100 of 116 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html
Ran from Feb 2020 to primary completion in Jun 2023, 40 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 40 months is below that.
Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Bempegaldesleukin